Yamamoto N - Search Results

1

Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance.

Yamamoto N, Kamitani T, Kanda K, Ito Y, Hamada M, Ozaki M, Takeuchi N, Yamada T, Kawano M, Maekawa S, Kato T. Yamamoto N, et al. Cancer Sci. 2022 Sep;113(9):3110-3119. doi: 10.1111/cas.15439. Epub 2022 Jun 24. Cancer Sci. 2022. PMID: 35611470 Free PMC article.

2

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.

Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M; West Japan Thoracic Oncology Group (WJTOG). Yamamoto N, et al. Cancer. 2006 Aug 1;107(3):599-605. doi: 10.1002/cncr.22024. Cancer. 2006. PMID: 16804877 Free article. Clinical Trial.

3

[Lung cancer].

Ono A, Yamamoto N. Ono A, et al. Among authors: yamamoto n. Gan To Kagaku Ryoho. 2007 Mar;34(3):367-73. Gan To Kagaku Ryoho. 2007. PMID: 17353626 Review. Japanese.

4

Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.

Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A, Murakami H, Endo M, Takahashi T. Igawa S, et al. Among authors: yamamoto n. J Thorac Oncol. 2007 Aug;2(8):741-4. doi: 10.1097/JTO.0b013e31811f46f0. J Thorac Oncol. 2007. PMID: 17762341 Free article. Clinical Trial.

5

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. Kiura K, et al. Among authors: yamamoto n. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228. J Thorac Oncol. 2008. PMID: 18379357 Free article. Clinical Trial.

6

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.

Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Ohe Y, et al. Among authors: yamamoto n. Clin Cancer Res. 2008 Jul 1;14(13):4206-12. doi: 10.1158/1078-0432.CCR-07-5143. Clin Cancer Res. 2008. PMID: 18594001 Clinical Trial.

7

[Advances in chemotherapy for lung cancer].

Ono A, Yamamoto N. Ono A, et al. Among authors: yamamoto n. Gan To Kagaku Ryoho. 2008 Sep;35(9):1475-81. Gan To Kagaku Ryoho. 2008. PMID: 18799900 Japanese.

8

[Lung cancer].

Ayabe E, Kaira K, Yamamoto N. Ayabe E, et al. Among authors: yamamoto n. Gan To Kagaku Ryoho. 2009 Jan;36(1):21-5. Gan To Kagaku Ryoho. 2009. PMID: 19151561 Japanese.

9

A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.

Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S. Shirao K, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2009 Aug;64(3):557-64. doi: 10.1007/s00280-008-0904-6. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169687 Clinical Trial.

10

Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.

Igawa S, Takahashi T, Nakamura Y, Tsuya A, Ono A, Shukuya T, Murakami H, Endo M, Yamamoto N. Igawa S, et al. Among authors: yamamoto n. Anticancer Res. 2008 Nov-Dec;28(6B):3855-8. Anticancer Res. 2008. PMID: 19192640 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,247 results

Search Page